Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Calidi Biotherapeutics ( (CLDI) ) has provided an announcement.
Calidi Biotherapeutics announced its first quarter 2025 financial results and recent operational highlights, including the appointment of a new CEO and CMO with extensive biopharmaceutical experience. The company reported a net loss of $5.0 million for the quarter, a reduction from the previous year’s loss. Significant developments include the FDA clearance for their IND application for CLD-201, an allogeneic stem cell-based immunotherapy targeting solid tumors, and the presentation of new preclinical data on their Redtail platform at the AACR Annual Meeting. These advancements position Calidi as a key player in the development of systemic oncolytic targeted immunotherapies, with potential implications for stakeholders in the biotechnology and healthcare sectors.
The most recent analyst rating on (CLDI) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, California, focused on developing targeted immunotherapies. Their proprietary Redtail platform uses an engineered enveloped oncolytic virus for systemic delivery to metastatic sites, aiming to shield the virus from immune clearance and deliver potent gene therapies.
Average Trading Volume: 433,909
Technical Sentiment Signal: Sell
Current Market Cap: $14.91M
Learn more about CLDI stock on TipRanks’ Stock Analysis page.